In the News
| DocWire News |  Dr. Camidge Discusses Launch of Phase 2 Trial Evaluating RAF/MEK Inhibitor in NSCLC |
13-Jan-21 |
| OncLive | RAF/MEK Inhibitor VS-6766 Plus Defactinib Under Exploration in Recurrent Low-Grade Serous Ovarian Cancer | 6-Jan-21 |
| Oncology Tube |  D. Ross Camidge, M.D., Ph.D @CUAnschutz @VerastemOncolog #NSCLC #RAMP202 #Cancer #Research Phase 2 Registration-Directed Trial of VS-6766 and Defactinib |
23-Dec-20 |
| BioWorld | In the clinic for Dec. 15, 2020 | 15-Dec-20 |
| BioPharma Journal | Verastem Oncology (NASDAQ:VSTM) Commence Phase 2 VS-6766 Study in Low-Grade Serous Ovarian Cancer Patients | 9-Dec-20 |
| DocWire News |  Drs. Banerji and Pachter Talk About RAF/MEK Inhibitor in RAS Mutant Tumors |
2-Dec-20 |
| Pharma Premium | Verastem Oncology Initiates Phase 2 Registration-Directed Trial of VS-6766 and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer | 30-Nov-20 |
| Precision Oncology News | Verastem Oncology Launches Phase II Trial of MEK, Pan-RAF Inhibitor in Ovarian Cancer | 30-Nov-20 |
| Oncology Tube |  Udai Banerji, MD @udai_banerji @IRC_London @royalmarsden @VerastemOncolog #KRASMutations #cancer #research VS-6766, a unique inhibitor of the RAF/MEK signaling pathway for patients |
6-Nov-20 |
| Cancer Health | KRAS Inhibitors Show Promise in Early Studies | 5-Nov-20 |
| Onco’Zine | Investigator-Initiated Study Supports Potential of VS-6766 as Treatment for RAS Mutant Tumors | 29-Oct-20 |